November 23, 2024

Healing Power of Light: Biomimetic Materials Pulsed With Low-Energy Blue Light Can Reshape Damaged Corneas

An injectable biomaterial activated by pulses of low-energy blue light has remarkable capacity for on-the-spot repair work to the domed external layer of the eye, a team of University of Ottawa researchers and their collaborators have revealed. Credit: Faculty of Medicine, University of Ottawa
A new study reveals that biomimetic products, when pulsed with low-energy blue light, can reshape damaged corneas, including increasing their density. The findings have the possible to affect countless people.
A team of University of Ottawa scientists and their partners have discovered the tremendous potential of an injectable biomaterial that is set off by low-energy blue light pulses for instant repair of the eyes domed external layer.
Following a design approach assisted by biomimicry– development that takes motivation from nature– the multidisciplinary researchers compelling outcomes reveal that an unique light-activated product can be utilized to efficiently improve and thicken broken corneal tissue, promoting healing and healing.

When pulsed with low-energy blue light, the injected peptide-based hydrogel hardens and types into a tissue-like 3D structure within minutes. Dr. Alarcon says this then becomes a transparent material with similar properties to those determined in pig corneas.
The research group– which employed a much smaller sized blue light dose compared to whats been utilized in other research studies– likewise successfully tested the technology in an ex vivo pig cornea model.” Our material was crafted to collect the blue light energy to set off the on-the-spot assembling of the product into a cornea-like structure. We anticipate our product will stay steady and be non-toxic in human corneas,” says Dr. Alarcon, whose uOttawa laboratory focuses on developing brand-new materials with regenerative abilities for tissue of the heart, cornea, and skin.

This innovation is a prospective game-changer in corneal repair; 10s of millions of people around the world struggle with corneal diseases and only a small fraction are qualified for corneal transplantation. Transplant operations are the present gold standard for disorders resulting in thinning corneas such as keratoconus, a poorly understood eye illness that leads to loss of vision for many individuals.
” Our innovation is a leap in the field of corneal repair work. We are confident this might become a practical option to deal with patients coping with diseases that adversely effect corneal shape and geometry, including keratoconus,” says Dr. Emilio Alarcon, an Associate Professor at the uOttawa Faculty of Medicine and scientist at the BioEngineering and Therapeutic Solutions (BEaTS) group at the University of Ottawa Heart Institute.
The cornea is the protective, dome-like surface of the eye in front of the iris and student. It controls and directs light rays into the eye and helps accomplish clear vision.
Dr. Emilio Alarcon, an Associate Professor at the University of Ottawas Faculty of Medicine and researcher at the BioEngineering and Therapeutic Solutions (BEaTS) group at the University of Ottawa Heart Institute. Credit: Faculty of Medicine, University of Ottawa
The collaborative groups work was released in Advanced Functional Materials, a high-impact clinical journal.
When pulsed with low-energy blue light, the injected peptide-based hydrogel hardens and forms into a tissue-like 3D structure within minutes. Dr. Alarcon states this then ends up being a transparent material with comparable properties to those determined in pig corneas.
In vivo experiments utilizing a rat model suggested that the light-activated hydrogel might thicken corneas without negative effects. The research study team– which utilized a much smaller blue light dose compared to whats been used in other studies– likewise successfully tested the innovation in an ex vivo pig cornea design. Testing in large animal models will be necessary previous to clinical human trials.
” Our material was engineered to collect the blue light energy to set off the on-the-spot assembling of the product into a cornea-like structure. Our cumulative information indicates that the materials are non-toxic and stay for a number of weeks in an animal design. We anticipate our material will remain steady and be non-toxic in human corneas,” says Dr. Alarcon, whose uOttawa lab focuses on establishing brand-new products with regenerative capabilities for tissue of the skin, cornea, and heart.
The strenuous research took over 7 years to reach the publication phase.
” We needed to engineer each part of the parts associated with the technology, from the light to the molecules used in the research study. The technology was established to be clinically translatable, meaning all elements should be developed to be eventually manufacturable following rigorous standards for sterility,” Dr. Alarcon states.
The research findings are also the focus of a patent application, which is currently under negotiations for licensing.
Dr. Alarcon was the studys senior author who directed the product design element of the research, while uOttawas Dr. Marcelo Muñoz and Aidan MacAdam played huge roles in developing the unique innovation. Interdisciplinary collaborators consisted of Université de Montréal researchers Dr. May Griffith, a professional in cornea regeneration, and Dr. Isabelle Brunette, an ophthalmology and corneal transplant specialist.
Reference: “Low Energy Blue Pulsed Light-Activated Injectable Materials for Restoring Thinning Corneas” by Aidan J. MacAdam, Marcelo Munoz, Jinane El Hage, Kevin Hu, Alex Ross, Astha Chandra, Jodi D. Edwards, Zian Shahid, Sophia Mourcos, Maxime E. Comtois-Bona, Alejandro Juarez, Marc Groleau, Delali Shana Dégué, Mohamed Djallali, Marilyse Piché, Mathieu Thériault, Michel Grenier, May Griffith, Isabelle Brunette and Emilio I. Alarcon, 19 July 2023, Advanced Functional Materials.DOI: 10.1002/ adfm.202302721.
The project was supported by a Collaborative Health Research Projects grant, an NSERC Discovery grant, the Government of Ontario, and the University of Ottawa Heart Institute.